Stock Scorecard
Stock Summary for Prelude Therapeutics Inc (PRLD) - $2.23 as of 12/26/2025 3:33:23 PM EST
Total Score
11 out of 30
Safety Score
20 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PRLD
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PRLD
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PRLD
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PRLD
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PRLD (20 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PRLD
Financial Details for PRLD
Company Overview |
|
|---|---|
| Ticker | PRLD |
| Company Name | Prelude Therapeutics Inc |
| Country | USA |
| Description | Prelude Therapeutics Inc. is a clinical-stage oncology company headquartered in Wilmington, Delaware, dedicated to innovating precision small molecule therapies that directly target key oncogenic drivers. The company is advancing a promising pipeline bolstered by its proprietary drug discovery platform, which focuses on delivering novel treatment options for patients afflicted with advanced cancers. With an unwavering commitment to precision medicine and a strategic vision for addressing underserved oncology needs, Prelude Therapeutics represents a compelling investment opportunity for institutional investors seeking to capitalize on growth in the biotech sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/18/2026 |
Stock Price History |
|
| Last Day Price | 2.23 |
| Price 4 Years Ago | 12.45 |
| Last Day Price Updated | 12/26/2025 3:33:23 PM EST |
| Last Day Volume | 107,876 |
| Average Daily Volume | 480,696 |
| 52-Week High | 4.22 |
| 52-Week Low | 0.61 |
| Last Price to 52 Week Low | 265.57% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 72.45 |
| Sector PE | 128.95 |
| 5-Year Average PE | -2.36 |
| Free Cash Flow Ratio | 2.35 |
| Industry Free Cash Flow Ratio | 14.50 |
| Sector Free Cash Flow Ratio | 31.21 |
| Current Ratio Most Recent Quarter | 3.21 |
| Total Cash Per Share | 0.95 |
| Book Value Per Share Most Recent Quarter | 0.77 |
| Price to Book Ratio | 2.63 |
| Industry Price to Book Ratio | 11.14 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 14.67 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.21 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 50,015,000 |
| Market Capitalization | 111,533,450 |
| Institutional Ownership | 54.48% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -4.38% |
| Reported EPS 12 Trailing Months | -1.47 |
| Reported EPS Past Year | -1.09 |
| Reported EPS Prior Year | -1.68 |
| Net Income Twelve Trailing Months | -111,772,000 |
| Net Income Past Year | -127,173,000 |
| Net Income Prior Year | -121,832,000 |
| Quarterly Revenue Growth YOY | 116.70% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -314.10% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 47,532,000 |
| Total Cash Past Year | 12,474,000 |
| Total Cash Prior Year | 25,291,000 |
| Net Cash Position Most Recent Quarter | 47,532,000 |
| Net Cash Position Past Year | 12,474,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 131,459,000 |
| Total Stockholder Equity Prior Year | 237,090,000 |
| Total Stockholder Equity Most Recent Quarter | 58,534,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -100,285,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.01 |
| Free Cash Flow Past Year | -103,652,000 |
| Free Cash Flow Prior Year | -110,576,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.17 |
| MACD Signal | 0.11 |
| 20-Day Bollinger Lower Band | 0.77 |
| 20-Day Bollinger Middle Band | 1.45 |
| 20-Day Bollinger Upper Band | 2.12 |
| Beta | 1.06 |
| RSI | 66.53 |
| 50-Day SMA | 1.09 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/27/2025 6:12:48 AM EST |